Y-Intercept (HK)
DNLI icon

Y-Intercept (HK)’s Denali Therapeutics DNLI Stock Holding History

Y-Intercept (HK)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$596K Buy
+28,847
New +$675K 0.01% 1232
2026
Q2 		– Sell
-78,007
Closed -$1.5M – 1812
2026
Q1 		$1.5M Sell
78,007
-15,580
-17% -$310K 0.03% 854
2025
Q4 		$1.55M Buy
+93,587
New +$1.58M 0.03% 750
2025
Q2 		– Sell
-54,813
Closed -$745K – 1710
2025
Q1 		$745K Buy
54,813
+18,807
+52% +$360K 0.05% 526
2024
Q4 		$734K Buy
36,006
+22,183
+160% +$568K 0.05% 558
2024
Q3 		$403K Sell
13,823
-25,369
-65% -$629K 0.02% 881
2024
Q2 		$910K Buy
+39,192
New +$752K 0.05% 534
2023
Q4 		– Sell
-26,618
Closed -$549K – 1322
2023
Q3 		$549K Buy
+26,618
New +$675K 0.05% 532
2021
Q2 		– Sell
-4,886
Closed -$265K – 682
2021
Q1 		$265K Buy
+4,886
New +$327K 0.07% 457

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Y-Intercept (HK)'s DNLI Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Denali Therapeutics (DNLI) in Q3 2026: 28,847 shares worth $596K. The stake represents 0.01% of the portfolio and ranks #1232 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in DNLI as recently as Q1 2026.

Y-Intercept (HK) first reported a position in DNLI in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.55M in Q4 2025. 140 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Y-Intercept (HK) held 28,847 shares of Denali Therapeutics worth $596K as of Q3 2026.
  • Denali Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
  • Denali Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1232 holding.
  • Y-Intercept (HK) first reported a position in Denali Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Y-Intercept (HK)'s Denali Therapeutics position peaked at $1.55M in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.